DUBLIN–(BUSINESS WIRE)–The “Diabetic
Nephropathy Market and Forecast Analysis to 2026” report has
been added to ResearchAndMarkets.com’s offering.
Diabetic nephropathy, also known as diabetic kidney disease, is caused
by damage to small blood vessels which can cause the kidneys to be less
efficient in their blood filtration role or to fail altogether. The
disease is a clinical syndrome characterized by albuminuria, decline in
glomerular filtration rate, and elevated arterial blood pressure. Up to
50% of diabetics with a disease duration of over 20 years have diabetic
nephropathy.
Market Snapshot
-
An ADA/EASD consensus report will help spur use of SGLT-2 inhibitors
in DN patients. -
Survey of 216 physicians in the US, Japan, and five major EU markets
sheds light on prescribing patterns. -
In parallel with diabetes, an increase in the prevalence burden of
diabetic nephropathy cases is expected during 2017-37. -
In-depth analysis of drug classes used for the treatment of diabetic
nephropathy in the US, Japan, and five major EU markets. - Drugs with a cardiovascular benefit will have an advantage in DN.
Key Topics Covered:
FORECAST: DIABETIC NEPHROPATHY (Published on 07 February 2019)
Overview
Recent Forecast Updates
Market Dynamics And Pipeline Assessment
Forecast
Market Definition And Methodology
Bibliography
Primary Research Methodology
Product Profile (Late Stage): Farxiga
Product Profile (Late Stage): Invokana
Product Profile (Late Stage): Jardiance
Product Profile (Late Stage): Finerenone
TREATMENT: DIABETIC NEPHROPATHY (Published on 05 February 2018)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Guideline Recommendations
Prescribing Trends
EPIDEMIOLOGY: DIABETIC NEPHROPATHY (Published on 30 October 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: DIABETIC NEPHROPATHY (Published on 07 February
2019)
Overview
Executive Summary
Ace Inhibitors
Angiotensin Ii Receptor Blockers
PIPELINE: DIABETIC NEPHROPATHY (Published on 07 February 2019)
Overview
Clinical Pipeline Overview
Target Product Profile
Clinical Trial Design
Recently Discontinued Drugs
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Farxiga
Product Profile (Late Stage): Invokana
Product Profile (Late Stage): Jardiance
Product Profile (Late Stage): Finerenone
For more information about this report visit https://www.researchandmarkets.com/r/2rmw6t
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Liver
and Kidney Disorders Drugs , Endocrine
and Metabolic Disorders Drugs